Evidence map›Paper›PMID 40702205›Full record

ArticlePediatric research2026

Paradoxical psoriasis in pediatric tumor necrosis factor-α inhibitor therapy database.

Yurong Piao, Xiaolin Xu, Xingfeng Yao, Yan Li, Yixin Sun, Tongxin Han, Xiaoling Wang, Huawei Mao

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yurong Piao *Department of Immunology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Xiaolin Xu *Department of Immunology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Xingfeng Yao *Department of Pathology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Yan LiDepartment of Immunology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Yixin SunDepartment of Pharmacy, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Tongxin HanDepartment of Immunology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Xiaoling WangDepartment of Pharmacy, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
Huawei MaoDepartment of Immunology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. maohwei@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParadoxical psoriasis (PP) is a class of adverse events associated with tumor necrosis factor α inhibitor (TNFi) that are realistically observed in the real world. We aim to quantify the signals of PP with TNFis in pediatric patients based on a pharmacovigilance study.

methodsData on pediatric PP cases linked to five TNFi drugs-etanercept, infliximab, adalimumab, certolizumab, and golimumab-were extracted from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q1 2023). PP event reports were assessed using ROR, PRR, BCPNN, MGPS, and logistic regression to conduct a disproportionality analysis and identify signal disparities.

resultsThe FAERS database noted 563 pediatric PP cases, with 33.69% male and 66.31% female, representing 0.58% of all pediatric TNFi adverse event reports. The average age was 14 years. Among the five TNFis, four showed disproportionate reporting of PP: etanercept [ROR = 18.53], infliximab [ROR = 17.19], adalimumab [ROR = 10.23], and certolizumab [ROR = 3.95].

conclusionsThe real-world FAERS pharmacovigilance data showed the safety signal for PP associated with TNFi in pediatric patients. Etanercept, infliximab, adalimumab, and certolizumab showed disproportionate reporting. IMPACT: This study collected and analysed the data of paradoxical psoriasis (PP) associated with TNFis in pediatric patients from a worldwide pharmacovigilance database. Reports of PP adverse events accounted for 0.58% of the overall TNFi adverse event reports in pediatric patients. Among the five TNFis, we found disproportionate reporting of PP with etanercept, infliximab, adalimumab, and certolizumab in pediatric patients.

Indexed as

PsoriasisTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAdalimumabAdolescentAdverse Drug Reaction Reporting SystemsAntibodies, MonoclonalCertolizumab PegolChildChild, PreschoolDatabases, FactualEtanerceptFemaleHumansInfliximabMaleAdalimumabAntibodies, MonoclonalCertolizumab PegolEtanerceptgolimumabInfliximabTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Identifiers

PMID40702205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.